drugset / Trial / NCT05515185

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

NCT05515185

Phase 0 Unknown 30 enrolled The First People's Hospital of Lianyungang
NaSingle-groupOpen-labelTreatment

Summary

This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.

Timeline

Start
2022-09-09
Primary completion
2024-09-08
Completion
2024-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject KT095 CAR-T Cell therapy Intravenous
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule

Indications